Bold Moves

Deliver first-in-class science

Transform our go-to-market model

In the fight against COVID-19, delivering an authorized vaccine and ensuring rapid, and equitable, access and uptake are critical to help address the global health crisis

For most of 2020, COVID-19 dramatically impacted people’s lives worldwide. Pfizer began taking steps at the start of the pandemic to follow its purpose - Breakthroughs that change patients’ lives - while harnessing the full breadth of resources to address the crisis. As a result, Pfizer and German biotechnology company BioNTech SE announced in March their collaboration to jointly develop a COVID-19 vaccine using BioNTech’s messenger RNA (mRNA) vaccine program. In parallel to the research and development process, Pfizer also made significant self-funded investment at-risk to scale up its manufacturing capacity and distribution infrastructure. The goal was to bring a potential vaccine, subject to regulatory authorization, to the world faster than Pfizer has ever done before but with the same rigor and commitment to quality and safety.

Vials of Pfizer’s COVID-19 vaccine being prepared for shipment at the company’s Puurs, Belgium, site.

Our objective was to ensure rapid uptake and equitable and affordable access for people who will need a vaccine, by contracting directly with governments for advance purchases. The extraordinary circumstances of the COVID-19 pandemic emphasize the need for procurement pathways that support rapid access, implementation and uptake. In a bold move, Pfizer and BioNTech developed a pricing model for the pandemic and worked closely with governments around the world to advance supply agreements. Our pandemic tiering pricing approach, with a not-for-profit price for Lower Income Countries / Lower-Middle Income Countries, prioritizes widespread access and enables a significant potential for cost savings to the health care system. In 2020, Pfizer and BioNTech finalized more than 25 agreements with individual governments or above market-governmental bodies around the world to supply their COVID-19 vaccine. By the end of 2020, the companies have produced approximately 50 million doses globally in markets where the vaccine became authorized. The companies aimed to manufacture at least two billion doses globally in total by the end of 2021 and are proud to be able to supply their vaccine to countries all over the world.1

Since the onset of the pandemic, Pfizer’s priority has been to develop a safe and effective vaccine, while simultaneously scaling up our manufacturing to deliver doses before the end of the year.”​​​​​​​

Dr. Albert Bourla

Chairman and Chief Executive Officer, Pfizer

Pfizer believes that vaccine access is a collective responsibility that demands highly coordinated and collaborative action by public and private stakeholders to help end the COVID-19 pandemic. The companies are committed to using their vaccine to help meet the current global public health need and will continue to work closely with international initiatives, governments and other vaccine manufacturers.

Pfizer's purpose is Breakthroughs that change patients’ lives, and in the 171-year history of the company, there has never been a more urgent need for a breakthrough to help alleviate the suffering of hundreds of thousands of people.

​​​​​The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at​​​​​​​


1Totals are subject to manufacturing capacity and regulatory approval or authorization and are based on updated 6-dose labeling and subject to continuous process improvements, expansion at current facilities and adding new contract suppliers and manufacturers.

​​​​​​​2The Tokyo 2020 Olympic Games will be celebrated from July 23 through August 8, 2021.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories